Posts

LRC-blau-TriCEPS-02

Next generation TriCEPS now available at Dualsystems Biotech

TriCEPSTM V.3.0 enables receptor identification for your orphan ligands at the surface of living cells without genetic manipulation.

Key features of the new TriCEPSTM V.3.0 and LRC- TriCEPSTM technology are: Read more

LRC-blau-TriCEPS-02

Dualsystems Biotech AG

Dualsystems Biotech AG


Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in the living cells especially at the cell membrane. We identify the targets of your extracellular ligands using the ligand-receptor capture LRC-TriCEPS™ technology. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment.

Further, with Flow-TriCEPS™ (Prestest TriCEPS™) we provide a tool to use in flow cytometry to identify the best binding conditions for your ligand of interest without the need of a detection antibody. Flow-TriCEPS can also be used in functional assays to test if TriCEPS coupled ligand is functionally active. Flow TriCEPS couples the ligand by using primary amines (N-Term and Lysines) and since it contains a biotin, can be detected by a streptavidin fluorophore conjugate using flow cytometry.

Flow TriCEPS Services/Kit



pretest-triceps-service-kit-yellow-flurescence1

Detection of the binding of your ligand to the cells using TriCEPS V2.0

Identification of the targets using TriCEPS V2.0 in or at the cell membrane of your ligand (peptide, protein, Antibody, ADC or other primary amine containing molecules) requires that the cells used are expressing the unknown targets. TriCEPS V2.0 is the ideal tool to screen cell lines or primary cells to identify the best cells to use later in the LRC-TriCEPS target identification experiments. Dualsystems offers these pretests for cell selection as service and kit. Needed for the experiment is the ligand of interest and the cell lines/ primary cells that are expected to express the unknown target. There is no need for a ligand specific antibody.

Used for:

  • Screening of different cells
  • Cell selection
  • Positive control selection
  • Negative control selection
  • Functional Assays with TriCEPS coupled ligand
  • Flow Cytometric (FACS) reagent to analyze protein/peptide binding to cells

A conceptual new approach for ligand-receptor capture on the living cell

Ligand receptor capture LRC-TriCEPS™ is a conceptually new technology to analyse the protein interaction of your biologics. We can identify the targets of your protein, antibody and peptide at the cell surface. Dualsystems offers the LRC-TriCEPS™ technology as a service for fee model to the industry and academia. The technology enables the unbiased identification of cell surface targets and off-targets on the living cells without genetic manipulation. Ligand-receptor capture technology can be used for many types of orphan ligands, such as peptides, proteins, antibodies, engineered affinity binders but also for viruses.

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses

Did you see our Video Interview about LRC-TriCEPS™ Services, ligand-receptor capture technology on the living cell?

Do you want to do functional pretests with your ligand coupled to LRC-TriCEPS™?

LRC-TriCEPS Service

LRC-TriCEPS™


Now available: The next generation of LCR-TriCEPS

TriCEPSTM V.3.0 enables receptor identification for your orphan ligands at the surface of living cells without genetic manipulation. Key features of the new TriCEPSTM V.3.0 and LRC- TriCEPSTM technology are:

  • Reduction of the number of cells needed:TriCEPS-next generation
  • TRICEPS V3.0 LRC experiments require 5-10 fold less starting material for successful receptor identification compared to TRICEPS V2.0.
  • High coverage of the surfaceome.
    • A modified LRC workflow enabled by TriCEPSTM V.3.0 allows for the theoretical identification of up to 85% of all putative cell surface proteins.
  • Identification of N-, C-, O- glycosylated targets
  • More sensitive identification of low copy number cell surface receptors through all tryptic

Decoding the extracellular interactome using LRC-TriCEPS™

A novel approach to analyse extracellular cell signaling by discovering cell surface receptors and off-targets for a ligand of interest on the living cell: label ligand with the LRC-TriCEPS™crosslinker, incubate with living cells or tissue expressing target receptor(s), purify receptor crosslinked peptides, analyse by LC-MS/MS. This new technology was invented by Andreas Frei and Bernd Wollscheid from the ETH Zurich who published the technology in Nature Biotechnology (Frei et al.(2012) Nature Biotechnology 30:997-1001).

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Viruses
  • Engineered affinity binders

Dualsystems Biotech AG, is a biotech company that provides services to analyse protein-protein interactions.

You are looking for the targets of your ligand (peptide, protein, antibody, and virus) that are relevant in the living organism? Give us a call +41 44 738 50 00 or fill in the form on the right side and we get in contact to see how the LRC-TriCEPS technology (ligand-receptor capture) can answer your question.


Ligand-receptor capture

LRC-TriCEPS™ (CaptiRec) is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Workflow-2016-April

Availability

The TriCEPS™-based ligand-receptor capture technology is now available.

Principle

Principle of LRC-TriCEPS™-based 

LRC-TriCEPS™ (CaptiRec) is a fast and sensitive approach to discover cell surface N-glycosylated receptors for a ligand of interest:

  • Label ligand with the TriCEPS™ chemoproteomic reagent
  • Activate target cells or native tissue to oxidize cell surface glycans
  • Incubate ligand-TriCEPS™ complex with activated cells
  • TriCEPS™ immediately links ligand and cognate receptor(s)
  • Isolate all membrane proteins
  • Tryptic digest of all membrane proteins
  • TriCEPS™-mediated purification of N-glycosylated peptides
  • Deglycosylation of peptides
  • Identification of peptides by mass spectrometry
  • Analysis of data using statistics and bioinformatics

LRC-TriCEPS™ – a trifunctional chemoproteomics reagentReceptor-mit-Ligand-Ausschnitt-2016-small

TriCEPS™ structure:

  • NHS-ester for attachment to the ligand
  • Protected hydrazine function for capturing the interacting receptor
  • Biotin function for purification of ligand-receptor peptides

Requirements

Requirements for one LRC experiment: Ligand in triplicate compared to control in triplicate

  • 300 µg ligand containing a free amino group
  • 600 Mio cells or 50 µm tissue slice

Examples of successful ligand-receptor capture (LRC) identifications

Ligand Target cells or tissue Receptors identified
Insulin Murine adipocytes, Jurkat cells Insulin receptor
Apelin-17 U2OS osteosarcoma cells Apelin receptor (GPCR)
Ankyrin repeat proteins BT-474 human breast
cancer cells
ErbB2, domain I
Vaccinia virus HeLa CCL2 cells AXL, M6PR, DAG1, CSPG4

From Frei et al. (2012) Nature Biotechnology 30:997

Publications

Licensing Agreement with ETH Zurich on LRC technoloy

Dualsystems Biotech closes Licensing Agreement with ETH Zurich on Ligand Receptor Capture (LRC) technology

Dualsystems Biotech has licensed an innovative technology to discover cell-surface receptors for a vast range of ligands of interest. LRC is centered around an innovative trifunctional chemoproteomic reagent named TriCEPS™, which enables the unbiased identification of cell surface receptors for many types of ligands, such as peptides, proteins, antibodies, engineered affinity binders or viruses. Receptor capture takes place under near-physiological conditions on native tissues and cells, without the need for genetic manipulations. Read more

Pages

LRC-blau-TriCEPS-02

Dualsystems Biotech AG

Dualsystems Biotech AG


Dualsystems Biotech is a service provider for custom proteomics for industry and academia. We are a biotech company specialized in elucidating protein-protein interaction in the living cells especially at the cell membrane. We identify the targets of your extracellular ligands using the ligand-receptor capture LRC-TriCEPS™ technology. During the interaction of your ligand of interest and its unknown targets and off-targets the cells are still alive and the unknown targets are in their natural microenvironment.

Further, with Flow-TriCEPS™ (Prestest TriCEPS™) we provide a tool to use in flow cytometry to identify the best binding conditions for your ligand of interest without the need of a detection antibody. Flow-TriCEPS can also be used in functional assays to test if TriCEPS coupled ligand is functionally active. Flow TriCEPS couples the ligand by using primary amines (N-Term and Lysines) and since it contains a biotin, can be detected by a streptavidin fluorophore conjugate using flow cytometry.

Flow TriCEPS Services/Kit



pretest-triceps-service-kit-yellow-flurescence1

Detection of the binding of your ligand to the cells using TriCEPS V2.0

Identification of the targets using TriCEPS V2.0 in or at the cell membrane of your ligand (peptide, protein, Antibody, ADC or other primary amine containing molecules) requires that the cells used are expressing the unknown targets. TriCEPS V2.0 is the ideal tool to screen cell lines or primary cells to identify the best cells to use later in the LRC-TriCEPS target identification experiments. Dualsystems offers these pretests for cell selection as service and kit. Needed for the experiment is the ligand of interest and the cell lines/ primary cells that are expected to express the unknown target. There is no need for a ligand specific antibody.

Used for:

  • Screening of different cells
  • Cell selection
  • Positive control selection
  • Negative control selection
  • Functional Assays with TriCEPS coupled ligand
  • Flow Cytometric (FACS) reagent to analyze protein/peptide binding to cells

A conceptual new approach for ligand-receptor capture on the living cell

Ligand receptor capture LRC-TriCEPS™ is a conceptually new technology to analyse the protein interaction of your biologics. We can identify the targets of your protein, antibody and peptide at the cell surface. Dualsystems offers the LRC-TriCEPS™ technology as a service for fee model to the industry and academia. The technology enables the unbiased identification of cell surface targets and off-targets on the living cells without genetic manipulation. Ligand-receptor capture technology can be used for many types of orphan ligands, such as peptides, proteins, antibodies, engineered affinity binders but also for viruses.

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Engineered affinity binders
  • Viruses

Did you see our Video Interview about LRC-TriCEPS™ Services, ligand-receptor capture technology on the living cell?

Do you want to do functional pretests with your ligand coupled to LRC-TriCEPS™?

LRC-TriCEPS Service

LRC-TriCEPS™


Now available: The next generation of LCR-TriCEPS

TriCEPSTM V.3.0 enables receptor identification for your orphan ligands at the surface of living cells without genetic manipulation. Key features of the new TriCEPSTM V.3.0 and LRC- TriCEPSTM technology are:

  • Reduction of the number of cells needed:TriCEPS-next generation
  • TRICEPS V3.0 LRC experiments require 5-10 fold less starting material for successful receptor identification compared to TRICEPS V2.0.
  • High coverage of the surfaceome.
    • A modified LRC workflow enabled by TriCEPSTM V.3.0 allows for the theoretical identification of up to 85% of all putative cell surface proteins.
  • Identification of N-, C-, O- glycosylated targets
  • More sensitive identification of low copy number cell surface receptors through all tryptic

Decoding the extracellular interactome using LRC-TriCEPS™

A novel approach to analyse extracellular cell signaling by discovering cell surface receptors and off-targets for a ligand of interest on the living cell: label ligand with the LRC-TriCEPS™crosslinker, incubate with living cells or tissue expressing target receptor(s), purify receptor crosslinked peptides, analyse by LC-MS/MS. This new technology was invented by Andreas Frei and Bernd Wollscheid from the ETH Zurich who published the technology in Nature Biotechnology (Frei et al.(2012) Nature Biotechnology 30:997-1001).

Orphan ligands:

  • Extracellular proteins
  • Peptide ligands
  • Antibodies
  • Viruses
  • Engineered affinity binders

Dualsystems Biotech AG, is a biotech company that provides services to analyse protein-protein interactions.

You are looking for the targets of your ligand (peptide, protein, antibody, and virus) that are relevant in the living organism? Give us a call +41 44 738 50 00 or fill in the form on the right side and we get in contact to see how the LRC-TriCEPS technology (ligand-receptor capture) can answer your question.


Ligand-receptor capture

LRC-TriCEPS™ (CaptiRec) is a novel approach which enables the identification of cell surface receptors and off-targets on the living cells for a wide range of orphan ligands, such as:

  • Peptides
  • Protein
  • Antibodies
  • Engineered affinity binders
  • Viruses

Workflow-2016-April

Availability

The TriCEPS™-based ligand-receptor capture technology is now available.

Principle

Principle of LRC-TriCEPS™-based 

LRC-TriCEPS™ (CaptiRec) is a fast and sensitive approach to discover cell surface N-glycosylated receptors for a ligand of interest:

  • Label ligand with the TriCEPS™ chemoproteomic reagent
  • Activate target cells or native tissue to oxidize cell surface glycans
  • Incubate ligand-TriCEPS™ complex with activated cells
  • TriCEPS™ immediately links ligand and cognate receptor(s)
  • Isolate all membrane proteins
  • Tryptic digest of all membrane proteins
  • TriCEPS™-mediated purification of N-glycosylated peptides
  • Deglycosylation of peptides
  • Identification of peptides by mass spectrometry
  • Analysis of data using statistics and bioinformatics

LRC-TriCEPS™ – a trifunctional chemoproteomics reagentReceptor-mit-Ligand-Ausschnitt-2016-small

TriCEPS™ structure:

  • NHS-ester for attachment to the ligand
  • Protected hydrazine function for capturing the interacting receptor
  • Biotin function for purification of ligand-receptor peptides

Requirements

Requirements for one LRC experiment: Ligand in triplicate compared to control in triplicate

  • 300 µg ligand containing a free amino group
  • 600 Mio cells or 50 µm tissue slice

Examples of successful ligand-receptor capture (LRC) identifications

Ligand Target cells or tissue Receptors identified
Insulin Murine adipocytes, Jurkat cells Insulin receptor
Apelin-17 U2OS osteosarcoma cells Apelin receptor (GPCR)
Ankyrin repeat proteins BT-474 human breast
cancer cells
ErbB2, domain I
Vaccinia virus HeLa CCL2 cells AXL, M6PR, DAG1, CSPG4

From Frei et al. (2012) Nature Biotechnology 30:997

Publications